Alnylam gets $7M milestone from Genzyme for rare disease drug

Alnylam Pharmaceuticals has received a $7 million milestone payment from partner Genzyme Corp. for its most advanced drug for a rare, inherited heart disease, following recently-released results from a mid-stage trial...
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.